

AGENDA

*Uniform Formulary Beneficiary Advisory Panel
12 January 2012 @ 0900 AM*

*Naval Heritage Center Theater
701 Pennsylvania Ave. NW., Washington DC 20004*

- **Administrative Meeting (BAP members only @ 7:30 AM-9:00 AM)**
- **Sign-In**
- **Welcome and Opening Remarks**
- **Public Citizen Comments**
- **Therapeutic Class Reviews**

Members of the DoD Pharmacoeconomic Center will present relative clinical and cost effective analyses along with the DoD Pharmacy & Therapeutics Committee recommendations for the Uniform Formulary.

The Committee made recommendations of the following drug classes during the Nov 2011 meeting:

- *Drug Class Reviews:*
 - *Depression and Non-Opioid Pain Syndrome Agents*
 - *Short-Acting Beta Agonists (SABAs)*
 - *Phosphodiesterase-5 Inhibitor (PDE-5) for Erectile Dysfunction (Cost effectiveness and Uniform Formulary/Prior Authorization)*
- *Designated Newly Approved Drugs:*
 - *Osteoporosis Agents — Risedronate delayed release tablets (Atelvia)*
- *Utilization Management*
 - *Tadalafil (Cialis) for Benign Prostatic Hypertrophy (BPH) Prior Authorization*
- **Panel Discussions**

The Uniform Formulary Beneficiary Advisory Panel will have the opportunity to ask questions to each of the presenters. Upon completion of the presentation and any questions, the Panel will discuss the recommendation and vote to accept or reject the recommendations. The Panel will provide comments on their vote as directed by the Panel Chairman.